JANUARY 15, 2013
Immune Globulins: Therapeutic, Pharmaceutical,
Cost, and Administration Considerations
Jerry Siegel, PharmD, FASHP
Independently developed by McMahon Publishing PHARMACY PRACTICE NEWS JANUARY 2013to consider product changes as if the patient is naive to Ig use, with increased monitoring and conservative infusion times.
Whereas Tables 1 to 5 may help facilitate these decisions, it is important to understand the clinical impact of changing products. Although all of the products contain primarily IgG, trace amounts of other Igs—IgA and IgM—as well as widely different stabilizing agents, may affect